Taragenyx announces appointment of Mark Wickham as Head of Technology
- Former Operations Director at Smith & Nephew (FTSE 100) joins Taragenyx -
Orthopaedic biotechnology company, Taragenyx Ltd., today
announced that Mark Wickham has been appointed as the company's Head of Technology.
Wickham, the former Operations Director of FTSE 100 quoted Smith & Nephew (LSE:SN), brings over 30 years experience in the medical device industry in Europe and the USA. He has recent and direct experience of managing fully autonomous R&D divisions and taking products to market across the medical devices field. His particular areas of professional interest are in the fields of novel drug delivery platforms, wound management orthopaedics.
“Mark is an exceptional leader who not only understands the management of growing R&D teams, but has the experience of successfully bringing device-drug combination products to the market,” said Iain McDougall, CEO of Taragenyx. "It's this unique combination of skill and expertise that makes Mark an outstanding professional, and I'm delighted to have him join us as Taragenyx continues to grow."
Wickham has a PhD in polymer chemistry from University of Reading, and holds an MBA from Henley Management College. He has an international R&D track record in orthopaedics, sports medicine, drug delivery, wound care and cardiology. His most prominent roles were as Operations Director for Smith & Nephew and as Head of Research and Development for Bespak developing drug delivery technologies. Both McDougall and Wickham are former employees of PA Consulting Group, one of the UK's leading consultancy firms specialising in technology and innovation.
Commenting on his appointment, Wickham said "I'm really excited about working with the Taragenyx team. They are a young, very energetic, and forward thinking company with an interesting approach on how to tackle the predominant challenges facing implant replacement across today's younger and more active patient population."
Taragenyx has pioneered the development of self-healing therapeutic implants aimed at tackling the
incredibly painful and expensive problem of orthopaedic implant failure. They are the youngest and only
biotech company on the prestigious London Stock Exchange ELITE Program for high growth businesses.